Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

AMLX

Amylyx Pharmaceuticals Inc

May 03 • 04:00PM ET

2.03

Dollar change +0.03
Percentage change 1.50	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IWM VBK VXF IWO IBB VTWO VHT FTLS

Index	RUT	P/E	2.88	EPS (ttm)	0.70	Insider Own	30.75%	Shs Outstand	67.71M	Perf Week	15.34%
Market Cap	138.06M	Forward P/E	-	EPS next Y	-1.32	Insider Trans	-0.13%	Shs Float	47.09M	Perf Month	-22.22%
Income	49.27M	PEG	-	EPS next Q	-0.00	Inst Own	88.51%	Short Float	13.83%	Perf Quarter	-87.14%
Sales	380.79M	P/S	0.36	EPS this Y	-328.33%	Inst Trans	32.39%	Short Ratio	1.90	Perf Half Y	-88.13%
Book/sh	6.40	P/B	0.32	EPS next Y	17.10%	ROA	10.84%	Short Interest	6.51M	Perf Year	-92.77%
Cash/sh	5.46	P/C	0.37	EPS next 5Y	-	ROE	12.73%	52W Range	1.70 - 30.50	Perf YTD	-86.21%
Dividend Est.	-	P/FCF	12.93	EPS past 5Y	-	ROI	11.32%	52W High	-93.34%	Beta	-0.68
Dividend TTM	-	Quick Ratio	5.20	Sales past 5Y	2300.59%	Gross Margin	93.03%	52W Low	19.41%	ATR (14)	0.27
Dividend Ex-Date	Mar 28, 2018	Current Ratio	5.66	EPS Y/Y TTM	130.51%	Oper. Margin	10.19%	RSI (14)	29.34	Volatility	8.76% 7.76%
Employees	384	Debt/Eq	0.01	Sales Y/Y TTM	1612.94%	Profit Margin	12.94%	Recom	2.71	Target Price	4.25
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	110.48%	Payout	0.00%	Rel Volume	0.43	Prev Close	2.00
Sales Surprise	1.39%	EPS Surprise	-69.27%	Sales Q/Q	395.54%	Earnings	May 09 BMO	Avg Volume	3.43M	Price	2.03
SMA20	-2.75%	SMA50	-66.63%	SMA200	-86.03%	Trades		Volume	1,475,388	Change	1.50%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-24	Downgrade	Mizuho	Buy → Neutral	$32 → $4
Mar-11-24	Downgrade	Robert W. Baird	Outperform → Neutral	$37 → $4
Mar-11-24	Downgrade	Leerink Partners	Outperform → Market Perform	$27 → $4
Mar-08-24	Downgrade	Goldman	Buy → Neutral
Mar-08-24	Downgrade	Evercore ISI	Outperform → In-line
Jan-03-24	Initiated	Robert W. Baird	Outperform	$37
Dec-12-23	Initiated	Deutsche Bank	Buy	$36
Jul-24-23	Upgrade	Goldman	Neutral → Buy	$45 → $49
Mar-31-23	Initiated	Mizuho	Buy	$52
Jan-05-23	Initiated	BofA Securities	Buy	$50
May-25-22	Initiated	Citigroup	Buy	$21
Apr-01-22	Downgrade	Goldman	Buy → Neutral	$36 → $10

Show Previous Ratings

May-02-24 09:00AM	Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire)
Apr-30-24 12:02PM	Trials to watch: Four ALS drugs to keep an eye on (Clinical Trials Arena)
Apr-10-24 03:14PM	Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder (Benzinga) -7.87%
09:00AM	Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome (Business Wire)
Apr-08-24 09:00AM	Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024 (Business Wire)
01:20PM	Loading…
Apr-04-24 01:20PM	Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70% (Zacks)
10:05AM	ALS drug will be pulled from US market after study showed patients didn't benefit (Associated Press Finance)
07:52AM	UPDATE 1-Amylyx Pharma to remove ALS drug from US, Canada markets (Reuters)
07:43AM	Amylyx Is Cutting 70% of Its Workforce and Pulling ALS Drug From the Market (Barrons.com)
07:07AM	Amylyx Pharmaceuticals to remove ALS drug from US, Canada markets (Reuters)
07:00AM	Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO/ALBRIOZA from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy (Business Wire)
06:09AM	Amylyx to pull ALS drug from market in rare move (BioPharma Dive)
Apr-03-24 05:45AM	Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire)
Apr-01-24 07:30PM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Mar-27-24 07:36AM	European study finds popular ALS drug ineffective (BioPharma Dive) +5.11%
02:33PM	Loading…
Mar-25-24 02:33PM	Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
Mar-14-24 06:49PM	3 Pharma Stocks to Sell in March Before They Crash & Burn (InvestorPlace) -7.85%
09:00AM	Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors (Business Wire)
Mar-13-24 10:00AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx (PR Newswire)
09:03AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Mar-12-24 07:55AM	After surprise trial failure, ALS doctors brace for one less treatment option (BioPharma Dive) -9.47%
Mar-11-24 12:34PM	Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82% (Zacks) +13.10%
07:45AM	Amylyx CEOs look for a path forward following major setback (BioPharma Dive)
Mar-10-24 08:00AM	Wall Street Predicted a Blockbuster. Now the Drug May Be Withdrawn. (The Wall Street Journal)
Mar-08-24 06:27PM	Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations (Business Wire) -82.29%
04:05PM	Amylyx Stock Wipes Out Nearly All Of Its Value, Crashing 82%, After Pivotal ALS Drug Failure (Investor's Business Daily)
11:30AM	Maker of much-debated ALS drug says it may stop selling it after study showed it didn't work (Associated Press Finance)
10:20AM	Amylyxs ALS Drug Fails Trial, Raising Questions About Companys Future (Barrons.com)
10:12AM	Amylyx Stock Crashes 80% After Approved ALS Drug Fails Its Pivotal Test (Investor's Business Daily)
09:38AM	10 Biotech Stocks with Huge Potential (Insider Monkey)
09:26AM	Loading…
09:26AM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
07:07AM	Amylyx's ALS drug fails in late-stage confirmatory study (Reuters)
07:00AM	Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS (Business Wire)
02:05AM	Amylyx ALS drug fails crucial study, putting companys future in doubt (BioPharma Dive)
Feb-27-24 05:45AM	Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire) +8.20%
Feb-26-24 11:39AM	AMLX NEWS: Johnson Fistel Encourages Amylyx Investors to Seek Counsel Before the Lead Plaintiff Deadline (GlobeNewswire)
Feb-25-24 06:30AM	7 Oversold Russell 2000 Stocks to Add to Your February Buy List (InvestorPlace)
Feb-23-24 04:05PM	Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
10:30AM	AMYLYX SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options (GlobeNewswire)
10:10AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:00AM	AMLX Stockholders with Significant Losses Should Contact Robbins LLP for Information About Their Rights and Remedies Against Amylyx Pharmaceuticals, Inc. (Business Wire)
05:45AM	Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AMLX (PR Newswire)
Feb-22-24 06:57PM	Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire) +21.10%
04:10PM	Amylyx Stock Rockets As ALS Drug Tacks On Another Triple-Digit Quarter (Investor's Business Daily)
08:15AM	Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 Earnings Estimates (Zacks)
07:35AM	Amylyx Pharmaceuticals Inc (AMLX) Reports Robust Revenue Growth and Net Income for Full Year 2023 (GuruFocus.com)
07:00AM	Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-20-24 05:45AM	Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire) -6.11%
Feb-19-24 12:40PM	Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
Feb-15-24 04:05PM	Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024 (Business Wire)
02:13PM	Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
09:00AM	Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference (Business Wire)
Feb-13-24 09:16PM	Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations (Business Wire) -7.94%
12:58PM	Get Rich Quick With These 3 Biotech Stocks to Buy Now (InvestorPlace)
Feb-12-24 08:09PM	Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
11:09AM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Feb-08-24 09:00AM	Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome (Business Wire)
Jan-26-24 03:57PM	3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024 (InvestorPlace)
Jan-21-24 01:16PM	3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024 (InvestorPlace)
Jan-14-24 12:54PM	7 Healthcare Stocks Taking Medicine to the Next Level (InvestorPlace)
Jan-05-24 05:34AM	2 Biotech Stocks With Huge Catalysts in 2024 (Motley Fool)
Dec-26-23 07:02PM	5 Best IPO Stocks to Buy Heading into 2024 (Insider Monkey)
08:48AM	Is Amylyx (AMLX) Stock a Solid Choice Right Now? (Zacks)
Dec-22-23 09:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP) (Business Wire)
Dec-11-23 08:36AM	Implied Volatility Surging for Amylyx (AMLX) Stock Options (Zacks)
Dec-04-23 09:00AM	Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS (Business Wire)
Nov-29-23 05:15PM	Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.19%
Nov-28-23 08:48AM	3 Top-Rated Biotech Stocks That Analysts Are Loving Now (InvestorPlace)
07:00AM	Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer (Business Wire)
Nov-27-23 09:00AM	RELYVRIO and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND (Business Wire)
Nov-21-23 09:00AM	Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-12-23 11:59AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 12:26AM	Q3 2023 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 05:04PM	Amylyx Crashes 32% On A Quarterly Report That Doesn't Bode Well For 2024 (Investor's Business Daily) -31.89%
12:12PM	Amylyx Crashes 27% As New ALS Drug Faces A Barrage Of Troubles (Investor's Business Daily)
08:05AM	Amylyx Pharmaceuticals Inc (AMLX) Reports Strong Q3 2023 Earnings with Significant Revenue Growth (GuruFocus.com)
07:00AM	Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-04-23 12:16PM	5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Nov-02-23 10:00AM	Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release (Zacks) +5.38%
09:00AM	Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023 (Business Wire)
Oct-19-23 09:00AM	Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium (Business Wire)
Oct-18-23 08:30AM	Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More (Zacks)
Oct-13-23 08:26AM	UPDATE 1-EU regulator declines to recommend Amylyx' ALS drug (Reuters)
07:55AM	EU regulator declines to recommend Amylyx' ALS therapy (Reuters)
07:45AM	Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process (Business Wire)
Oct-11-23 08:07AM	PTC Therapeutics (PTCT) Moves 5.3% Higher: Will This Strength Last? (Zacks)
Oct-10-23 09:45AM	2 Incredible Growth Stocks Near 52-Week Lows to Buy Now (Motley Fool)
09:12AM	Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control (Business Wire)
Oct-05-23 05:26PM	Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France (Business Wire)
Oct-02-23 09:00AM	RELYVRIO and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting (Business Wire)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
02:54AM	14 Best Depressed Stocks To Buy Now (Insider Monkey)
Sep-20-23 09:02AM	Marinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock? (Zacks)
Sep-05-23 09:00AM	Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire) -5.41%
Aug-28-23 11:53PM	3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List (InvestorPlace)
Aug-14-23 05:38AM	Amylyx's new ALS drug has turned a profit for six months straight (American City Business Journals)
Aug-13-23 08:26AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 08:47AM	Q2 2023 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 05:15PM	Amylyx Pharmaceuticals, Inc. (AMLX) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
04:01PM	Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results (Business Wire)

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Klee Justin B.	Co-Chief Executive Officer	Mar 05 '24	Sale	18.73	4,135	77,440	2,959,308	Mar 07 04:05 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 05 '24	Sale	18.73	4,135	77,440	3,023,002	Mar 07 04:05 PM
FRATES JAMES M	Chief Financial Officer	Mar 05 '24	Sale	18.73	1,792	33,560	134,784	Mar 07 04:05 PM
Mazzariello Gina	Chief Legal Officer	Mar 05 '24	Sale	18.73	1,540	28,841	81,372	Mar 07 04:05 PM
Mazzariello Gina	Chief Legal Officer	Feb 23 '24	Sale	18.76	2,838	53,231	46,245	Feb 27 05:59 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 09 '24	Sale	16.33	5,841	95,372	2,836,776	Jan 11 05:11 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 09 '24	Sale	16.33	5,841	95,372	2,900,470	Jan 11 05:10 PM
Yeramian Patrick D	Chief Medical Officer	Jan 09 '24	Sale	16.33	2,812	45,915	205,605	Jan 11 05:04 PM
FRATES JAMES M	Chief Financial Officer	Jan 09 '24	Sale	16.33	2,716	44,347	112,035	Jan 11 05:11 PM
Olinger Margaret	Chief Commercial Officer	Dec 27 '23	Option Exercise	0.37	25,000	9,250	276,108	Dec 29 04:07 PM
Firestone Karen	Director	Dec 15 '23	Buy	14.97	4,000	59,880	5,000	Dec 19 04:37 PM
Cohen Joshua B	Co-Chief Executive Officer	Nov 16 '23	Option Exercise	1.57	63,694	100,000	2,906,311	Nov 20 08:20 PM
FRATES JAMES M	Chief Financial Officer	Aug 23 '23	Option Exercise	6.88	18,165	124,975	106,341	Aug 24 04:15 PM
Mazzariello Gina	Chief Legal Officer	Aug 15 '23	Sale	20.88	6,164	128,686	49,083	Aug 17 04:35 PM
Olinger Margaret	Chief Commercial Officer	Jul 12 '23	Option Exercise	0.37	20,000	7,400	251,108	Jul 14 04:20 PM
FRATES JAMES M	Chief Financial Officer	May 16 '23	Option Exercise	6.88	32,500	223,600	88,176	May 18 08:54 PM
FRATES JAMES M	Chief Financial Officer	May 16 '23	Sale	26.94	32,500	875,451	55,676	May 18 08:54 PM
Yeramian Patrick D	Chief Medical Officer	May 15 '23	Option Exercise	5.68	11,965	67,991	220,382	May 17 04:58 PM
Yeramian Patrick D	Chief Medical Officer	May 15 '23	Sale	29.03	11,965	347,358	208,417	May 17 04:58 PM

Open in Screener

AUPH

Aurinia Pharmaceuticals Inc

May 03 • 04:00PM ET

5.10

Dollar change -0.07
Percentage change -1.35	%

Healthcare • Biotechnology • Canada • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

AUPH Aurinia Pharmaceuticals Inc daily Stock Chart

Held by: IWM IWO IBB VTWO VHT VTWG SBIO PRFZ VT FHLC

Index	RUT	P/E	-	EPS (ttm)	-0.44	Insider Own	11.59%	Shs Outstand	143.83M	Perf Week	3.87%
Market Cap	729.40M	Forward P/E	10.77	EPS next Y	0.47	Insider Trans	-1.92%	Shs Float	126.45M	Perf Month	0.20%
Income	-62.56M	PEG	-	EPS next Q	0.01	Inst Own	36.56%	Short Float	9.01%	Perf Quarter	-33.59%
Sales	191.41M	P/S	3.81	EPS this Y	112.96%	Inst Trans	9.06%	Short Ratio	5.37	Perf Half Y	-28.47%
Book/sh	2.50	P/B	2.04	EPS next Y	576.19%	ROA	-12.92%	Short Interest	11.39M	Perf Year	-56.37%
Cash/sh	2.24	P/C	2.28	EPS next 5Y	-	ROE	-16.69%	52W Range	4.71 - 12.43	Perf YTD	-43.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	6.35%	ROI	-14.44%	52W High	-58.97%	Beta	1.42
Dividend TTM	-	Quick Ratio	5.05	Sales past 5Y	3168.98%	Gross Margin	88.59%	52W Low	8.28%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	5.60	EPS Y/Y TTM	35.94%	Oper. Margin	-33.81%	RSI (14)	48.83	Volatility	7.17% 4.34%
Employees	300	Debt/Eq	0.25	Sales Y/Y TTM	30.37%	Profit Margin	-32.69%	Recom	1.62	Target Price	10.14
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	59.39%	Payout	-	Rel Volume	0.80	Prev Close	5.17
Sales Surprise	6.86%	EPS Surprise	48.79%	Sales Q/Q	46.19%	Earnings	May 02 BMO	Avg Volume	2.12M	Price	5.10
SMA20	1.51%	SMA50	-2.56%	SMA200	-34.26%	Trades		Volume	1,696,426	Change	-1.35%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight	$34 → $25
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform	$33 → $31
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform	$32
Jan-25-21	Reiterated	H.C. Wainwright	Buy	$30 → $35
Nov-03-20	Reiterated	H.C. Wainwright	Buy	$34 → $28
Jun-17-20	Initiated	BTIG Research	Buy	$20
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy	$27
Dec-16-19	Reiterated	H.C. Wainwright	Buy	$25 → $32
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight	$14 → $16
Feb-08-18	Initiated	RBC Capital Mkts	Outperform	$9
Oct-30-17	Reiterated	H.C. Wainwright	Buy	$10 → $12
May-18-17	Reiterated	H.C. Wainwright	Buy	$12 → $10
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight	$14
Mar-22-17	Reiterated	FBR & Co.	Outperform	$9 → $11
Dec-30-16	Reiterated	H.C. Wainwright	Buy	$10 → $8
Aug-17-16	Reiterated	H.C. Wainwright	Buy	$7 → $10
Jun-30-16	Initiated	H.C. Wainwright	Buy	$7
May-08-15	Initiated	MLV & Co	Buy	$9

Show Previous Ratings

May-03-24 01:02PM	Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 10:56AM	AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:10AM	Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:10AM	Aurinia: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results (Business Wire)
06:00AM	Loading…
May-01-24 06:00AM	Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month (Business Wire)
Apr-30-24 06:00AM	The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program (Business Wire)
Apr-16-24 10:48AM	UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference (Business Wire)
Apr-15-24 06:00AM	Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024 (Business Wire)
Apr-09-24 06:00AM	Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference (Business Wire)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Feb-29-24 08:30AM	Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program (Business Wire)
Feb-27-24 08:30AM	Aurinia to Participate in Upcoming Investor Healthcare Conferences (Business Wire)
Feb-16-24 09:22AM	Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-15-24 07:25AM	Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -24.47%
06:49AM	Loading…
06:49AM	Aurinia Pharmaceuticals Inc (AUPH) Announces Year-End Financial Results and Strategic Initiatives (GuruFocus.com)
06:32AM	Aurinia: Q4 Earnings Snapshot (Associated Press Finance)
06:19AM	UPDATE 2-Aurinia Pharma fails to sell itself; to stop trials, cut jobs, buy back shares (Reuters)
06:10AM	Aurinia to cut research after sale process fails to find a buyer (BioPharma Dive)
06:07AM	Aurinia to stop R&D on immunotherapies to focus on kidney disease drug (Reuters)
06:00AM	Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value (Business Wire)
Feb-08-24 10:00AM	Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-05-24 08:30AM	Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024 (Business Wire)
Jan-18-24 04:30PM	Kane Biotech Announces Special Meeting of Shareholders (GlobeNewswire)
Jan-05-24 06:00AM	Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results (Business Wire)
Dec-28-23 09:40AM	Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year? (Zacks)
Dec-20-23 06:00AM	Aurinia Submits IND Application to US Food & Drug Administration for AUR 200 (Business Wire) -6.11%
Dec-10-23 06:59AM	This Small Pharma Could Be Targeted, But Would Be Fine Alone, Too (TheStreet.com)
Nov-23-23 09:55AM	Can Aurinia (AUPH) Climb 46.13% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-20-23 09:40AM	Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year? (Zacks) +7.44%
06:00AM	Loading…
Nov-13-23 06:00AM	Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS (Voclosporin) in Japan (Business Wire)
Nov-07-23 10:30AM	Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNIS (voclosporin) for Patients with Lupus Nephritis at ACR 2023 (Business Wire)
09:55AM	Wall Street Analysts See a 59.35% Upside in Aurinia (AUPH): Can the Stock Really Move This High? (Zacks)
Nov-03-23 09:40AM	Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year? (Zacks)
08:46AM	Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 06:00PM	Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS for Managing Lupus Nephritis (Business Wire) +10.52%
07:50AM	Aurinia Pharmaceuticals Inc (AUPH) Reports 60% Increase in Q3 Net Product Revenue (GuruFocus.com)
07:15AM	Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:10AM	Aurinia: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results (Business Wire)
Oct-26-23 03:00PM	Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis (Business Wire)
Oct-19-23 10:31AM	CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023 (Business Wire)
06:00AM	Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023 (Business Wire)
Oct-16-23 09:29AM	Pfizer (PFE) Cuts 2023 Outlook as COVID Products' Demand Falls (Zacks) +5.32%
Oct-14-23 01:15PM	13 Stocks to Buy with Exponential Growth (Insider Monkey)
Oct-13-23 12:00PM	Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR) (Business Wire)
Oct-12-23 12:13PM	Lilly (LLY) Up on NVO's Ozempic Early Success in Kidney Study (Zacks)
Oct-11-23 10:15AM	Merck's (MRK) Keytruda Early-Stage NSCLC Study Shows OS Benefit (Zacks)
Oct-09-23 11:10AM	J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC (Zacks)
Oct-06-23 09:24AM	AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker (Zacks)
Oct-04-23 08:17AM	AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M (Zacks)
Oct-03-23 07:43AM	Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection (Zacks)
Sep-29-23 09:40AM	Are Medical Stocks Lagging Align Technology (ALGN) This Year? (Zacks)
Sep-27-23 09:34AM	Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)? (Zacks)
Sep-26-23 10:56AM	AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL (Zacks)
Sep-21-23 06:00AM	Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital (Business Wire)
Sep-18-23 08:52AM	5 Stocks to Buy as Drug Industry Displays Strong Fundamentals (Zacks)
Sep-06-23 09:55AM	Wall Street Analysts Think Aurinia (AUPH) Could Surge 42.86%: Read This Before Placing a Bet (Zacks)
Aug-25-23 09:40AM	Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-21-23 06:00AM	Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines (Business Wire)
Aug-03-23 07:15AM	Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:11AM	Aurinia: Q2 Earnings Snapshot (AP Finance)
06:00AM	Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results (Business Wire)
Jul-27-23 07:41AM	Institutions own 42% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares but individual investors control 56% of the company (Simply Wall St.)
Jul-20-23 06:00AM	Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023 (Business Wire)
Jul-19-23 12:05PM	Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events (Business Wire)
Jul-18-23 10:55AM	Aurinia Pharmaceuticals Stock Returns To A Rising Relative Strength (Investor's Business Daily)
Jul-11-23 10:55AM	Aurinia Pharmaceuticals Stock Shows Rising Relative Strength (Investor's Business Daily) +6.24%
Jul-03-23 10:42AM	Aurinia (AUPH) Up on Paving the Way for a Potential Buyout (Zacks)
Jul-02-23 05:59PM	Aurinia (AUPH) Moves 5.7% Higher: Will This Strength Last? (Zacks)
Jun-30-23 04:02PM	Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential Buyout (Investor's Business Daily) +5.68%
02:49PM	Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday (Motley Fool)
Jun-29-23 04:05PM	Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value (Business Wire)
Jun-20-23 09:00AM	Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy (Business Wire)
Jun-06-23 08:11AM	Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Shares Lagging The Industry But So Is The Business (Simply Wall St.) +5.35%
Jun-01-23 09:00AM	LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone (Business Wire)
May-26-23 05:16PM	Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees (Business Wire)
May-23-23 06:56AM	Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Shift From Loss To Profit (Simply Wall St.)
May-17-23 12:14PM	Aurinia Announces 2023 Annual General Meeting Results (Business Wire)
May-11-23 12:00PM	Here's Why Aurinia Pharmaceuticals (AUPH) is a Great Momentum Stock to Buy (Zacks)
May-09-23 06:02AM	News Flash: Analysts Just Made A Sizeable Upgrade To Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Forecasts (Simply Wall St.)
06:00AM	Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference (Business Wire)
May-04-23 07:15AM	Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:11AM	Aurinia: Q1 Earnings Snapshot (AP Finance)
06:00AM	Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results (Business Wire)
May-03-23 07:51AM	Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis (Business Wire)
May-02-23 04:36PM	ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual General Meeting (Business Wire)
12:00PM	Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin) (Business Wire)
Apr-28-23 06:30AM	Glass Lewis Recommends Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual Meeting (Business Wire)
Apr-26-23 11:30AM	3 Biotechs That Might Get Bought Out in 2023 (Motley Fool)
Apr-25-23 11:00AM	Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys (Business Wire)
Apr-24-23 05:10PM	Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday (Benzinga)
06:00AM	Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023 (Business Wire)
Apr-12-23 12:34PM	Aurinia (AUPH) Up 11% on Issue of New Additional Lupkynis Patent (Zacks)
Apr-11-23 02:41PM	Why Aurinia Pharmaceuticals Stock Is Glowing Green Today (Motley Fool) +10.84%
10:26AM	Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office (Business Wire)
05:39AM	3 Stocks That Already Doubled in 2023 and Could Keep Climbing (Motley Fool)
Apr-05-23 06:30AM	Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial (Business Wire)
Apr-04-23 06:42AM	We Think Aurinia Pharmaceuticals (NASDAQ:AUPH) Can Easily Afford To Drive Business Growth (Simply Wall St.)
Apr-03-23 04:00PM	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.84%

Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Greenleaf Peter	Chief Executive Officer	Mar 06 '24	Sale	5.60	126,981	711,094	1,522,114	Mar 07 04:46 PM
Robertson Stephen P.	EVP, General Counsel	Mar 06 '24	Sale	5.60	57,745	323,372	443,824	Mar 07 04:41 PM
Donley Matthew Maxwell	EVP, Ops & Strategy	Mar 06 '24	Sale	5.51	40,665	224,064	584,072	Mar 07 04:43 PM
Miller Joseph M	Chief Financial Officer	Mar 06 '24	Sale	5.60	34,811	194,942	495,928	Mar 07 04:44 PM
Habig Scott Michael	Chief Commercial Officer	Mar 06 '24	Sale	5.60	17,777	99,551	474,587	Mar 07 04:42 PM
Knappertz Volker	EVP, Research and Development	Feb 27 '24	Sale	6.10	4,930	30,073	319,128	Feb 29 04:11 PM
Knappertz Volker	EVP, Research and Development	Feb 20 '24	Sale	5.48	25,146	137,800	324,058	Feb 22 04:35 PM
Habig Scott Michael	Chief Commercial Officer	Feb 20 '24	Sale	5.48	15,867	86,951	492,364	Feb 22 04:33 PM
Jayne David R.W.	Director	May 23 '23	Sale	11.26	8,733	98,334	49,310	May 23 05:19 PM
MacKay-Dunn R. Hector	Director	May 23 '23	Sale	11.26	4,818	54,251	24,225	May 23 05:16 PM
Leversage Jill	Director	May 23 '23	Sale	11.26	4,815	54,217	18,528	May 23 05:14 PM
Billen Daniel	Director	May 23 '23	Sale	11.26	4,650	52,359	33,393	May 23 05:17 PM
Hagan Joseph P	Director	May 19 '23	Sale	10.58	272	2,878	11,961	May 23 05:18 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

AMLX

Amylyx Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

Upgrade your FINVIZ experience